|
시장보고서
상품코드
2052755
특발성 폐섬유증 시장 : 약물별, 투여 경로별, 유통 채널별, 지역별Idiopathic Pulmonary Fibrosis Market, By Drug, By Route of Administration, By Distribution Channel, and By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
특발성 폐섬유증 시장은 2026년에 53억 9,060만 달러로 추정되며, 2033년까지 97억 9,100만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 8.9%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 53억 9,060만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 8.90% | 2033년 시장 규모 예측: | 97억 9,100만 달러 |
특발성 폐섬유증(IPF)은 원인을 알 수 없는 만성적이고 진행성 섬유화를 동반한 간질성 폐렴의 일종으로 주로 노인의 폐에서 발생하며, 정상형 간질성 폐렴(UIP)의 조직병리학적 및/또는 방사선학적 소견과 관련이 있습니다. IPF의 진단을 위해서는 다른 특발성 간질성 폐렴(IIP), 환경 노출, 약물 또는 결합조직 질환과 관련된 간질성 폐질환(ILD)을 포함한 다른 형태의 간질성 폐렴을 배제해야 합니다.
시장 역학
특발성 폐섬유증의 유병률 증가가 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 7월 미국 국립의학도서관이 발표한 보고서에 따르면, 2021년 전 세계 특발성 폐섬유증 유병률은 인구 10만 명당 13-20명입니다. 2021년에는 미국에서 약 10만 명의 환자가 발생할 것으로 예상되며, 매년 3만-4만 명의 신규 확진자가 발생합니다.
미국 국립생물공학정보센터(NCBI)가 발표한 보고서에 따르면, 2022년 기준 인도의 특발성 폐섬유증 유병률은 약 13.7%로 나타났습니다.
또한, 특발성 폐섬유증의 유병률이 증가함에 따라 주요 시장 기업들은 신제품 출시에 주력하고 있으며, 이는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2022년 5월, 제네릭 의약품 및 바이오시밀러 분야의 세계 리더인 Sandoz는 특발성 폐섬유증(IPF) 환자 치료제로서 생명공학 기업 Genentech의 '에스브리'에 해당하는 최초의 AB 등급(항체)(완전 대체 가능) 제네릭 의약품인 의약품인 피르페니돈의 미국 출시를 발표했습니다. 이 경구용 약은 전문 약국을 통해 환자에게 처방됩니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 특발성 폐섬유증 시장의 주요 기업 프로파일을 작성했습니다. 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략입니다. 이번 조사에 포함된 주요 기업으로는 Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc 등이 있습니다.
- 이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 세계 특발성 폐섬유증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가를 포함한 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 특발성 폐섬유증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 특발성 폐섬유증 시장 : 약물별, 2021-2033년
제5장 세계의 특발성 폐섬유증 시장 : 투여 경로별, 2021-2033년
제6장 세계의 특발성 폐섬유증 시장 : 유통 채널별, 2021-2033년
제7장 세계의 특발성 폐섬유증 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.06.17Idiopathic Pulmonary Fibrosis Market is estimated to be valued at USD 5,390.6 Mn in 2026 and is expected to reach USD 9,791.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5,390.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.90% | 2033 Value Projection: | USD 9,791 Mn |
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.
Market Dynamics
Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2022, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2021. About 100,000 people were affected in the U.S., in 2021, whereas 30,000 to 40,000 new cases are diagnosed every year.
According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2022.
Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech's, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market.
Market Segmentation
- Global Idiopathic pulmonary fibrosis market, By Drug (Revenue, USD Mn, 2021 - 2033)
- Pirfenidone
- Nintedanib
- Others (Interferon gamma-1b and Others)
- Global Idiopathic pulmonary fibrosis market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral
- Parenteral
- Global Idiopathic pulmonary fibrosis market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Idiopathic pulmonary fibrosis market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Genentech, Inc.
- Boehringer Ingelheim International GmbH
- Avalyn Pharma, Inc.
- AstraZeneca
- Blade Therapeutics
- Bristol-Myers Squibb Company
- Cipla Inc.
- Hoffmann-La Roche
- FibroGen, Inc.
- Galapagos NV
- MediciNova, Inc.
- Merck & Co., Inc.
- Promedior, Inc.
- Prometic Life Sciences Inc.
- Daewoong Pharmaceutical (India) Pvt Ltd.
- Sandoz International GmbH (Novartis)
- Algernon Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Product Launches
- Merger, Acquisition, Collaboration
- Regulatory Guideline and Compliances
- Key Developments
- Market Trends
- PEST Analysis
- Epidemiology
- PORTER's Analysis
- Regulatory Scenario
- Brand Analysis
- Pricing Analysis
- Pipeline Analysis
4. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pirfenidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Nintedanib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others (Interferon gamma-1b and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segments Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2021 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Avalyn Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Blade Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- FibroGen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Galapagos NV
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- MediciNova, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Promedior, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Prometic Life Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Daewoong Pharmaceutical (India) Pvt Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sandoz International GmbH (Novartis)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Algernon Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
